Misty Dawn Shields, Assistant professor of clinical medicine at Indiana University, shared on X:
“Lung cancer survivor and WTOP DC news reporter Neal Augenstein kindly shares his life experience with Stage 4 EGFR altered lung cancer and remains NED for the past 3 years. A vital talk to shape perspectives on what truly matters as we start DCLung26.
Thankful for meaningful translational advances in targeted treatments and growing knowledge of resistance surrounding EGFR treatments over the past two decades.
Highlights need for ongoing reframing lung cancer screening criteria to capture every person at risk for developing lung cancer early.”
Other articles about DCLung26 on OncoDaily.